Molecular mechanism of Andrographis herba for breast cancer based on network pharmacology
10.3760/cma.j.cn115398-20191028-00080
- VernacularTitle:基于网络药理学探讨穿心莲治疗乳腺癌的作用机制
- Author:
Yue ZHONG
1
;
Xiangjun QI
;
Zhaoling LIN
;
Xiaoyan GU
;
Mei HUANG
Author Information
1. 广州中医药大学第一临床医学院 510405
- From:
International Journal of Traditional Chinese Medicine
2020;42(8):763-770
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Based on the methodology of network pharmacology, this study preliminarily predicted the major targets and pathways of Andrographis herba in the treatment of breast cancer. Methods:The active components of Andrographis herba were screened by Traditional Chinese Medicine Systems Pharmacology Database (TCMSP); breast cancer targets were predicted and screened by Genecard database platform and OMIM database platform; active ingredient-targets networks were built by Cytoscape (3.7.2) software, and protein interaction networks were built by String database platform. Finally, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed by using Bioconductor platform and R language. Results:A total of 24 active ingredients of Andrographis herba and 13 234 targets for breast cancer were obtained, involving 71 targets related to Andrographis herba. There were 51 common targets for Andrographis herba-breast cancer. The top five targets are TP53, IL6, JUN, CCND1, and ERS1. Andrographis herba-breast cancer KEGG-enriched pathways are estrogen signaling pathway, P53 signaling pathway, Notch signaling pathway, and Wnt signaling pathway. Conclusions:The TP53, ERS1, and CCND1 and other targets may be the key targets for Andrographis herba paniculata to treat breast cancer. It plays an anti-breast cancer effect by regulating the signal pathways such as the estrogen receptor pathway and the P53 signaling pathway. This paper provides a theoretical basis for further exploration of the mechanism research of Andrographis herba in the treatment of breast cancer.
